Hyphens Pharma International Ltd.
SSGX:1J50.35
SGD
-0.01
(-4.11%)
ISIN
SG1EE4000006
Return %
Stock
S&P 500
1Y
1.45
14.39
3Y
25.00
81.42
5Y
18.64
68.62
Capital Structure
SGD
•
in mil. unless spec.Working Capital
SGD
•
in mil. unless spec.Growth Rates
SGD
•
in mil. unless spec.Semi-annual Revenue
SGD
•
in mil. unless spec.Semi-annual Earnings Per Share
SGD
•
in mil. unless spec.Semi-annual Dividends Per Share
SGD
•
in mil. unless spec.Company Description
- CEO
- See Wah Lim
- Full Time Employees
- 474
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Singapore Singapore
- IPO Date
- May 18, 2018
- Website
- hyphensgroup.com
- Similar Companies
- Business
- Hyphens Pharma International Limited is a specialty pharmaceutical and consumer healthcare company. Established in 1998 and headquartered in Singapore, the company operates across three primary business segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. The Specialty Pharma Principals segment markets and distributes specialty pharmaceuticals and medical aesthetic products through exclusive licensing and distributorship agreements with brand principals primarily from Europe and the United States, covering therapeutic areas such as dermatology, pediatrics, allergy, cardiology, ophthalmology, radiology, and orthopedics; offerings include injectable botulinum toxins, disease-modifying antirheumatic therapies, and targeted topical treatments such as Nabota, Metoject, Wynzora, and Winlevi. The Proprietary Brands segment develops, commercializes, and markets proprietary dermatological formulations, specialized skincare solutions, and health supplements under owned trademarks, including Ceradan ceramide-dominant skin barrier repair creams, TDF (Therapeutic Dermatologic Formula) cosmeceuticals, Ocean Health vitamins and dietary supplements, CG210 hair and scalp essences, and Cerapro medical-grade skincare products. The Medical Hypermart and Digital segment provides wholesale distribution of pharmaceuticals, medical devices, and healthcare consumables through Pan-Malayan Pharmaceuticals Pte Ltd, as well as digital healthcare procurement systems, logistics solutions, and e-pharmacy services via subsidiaries including DocMed Technology Pte. Ltd. and the WellAway digital pharmacy platform. The company serves medical institutions, specialist clinics, general practitioners, retail pharmacies, and end-consumers. Geographically, the group maintains direct operations across Singapore, Malaysia, Vietnam, Indonesia, and the Philippines, complemented by an international marketing and distribution network spanning wider Asia and the Middle East. In recent corporate developments, Hyphens Pharma expanded its medical aesthetics footprint by acquiring an increased controlling stake in Ardence Pharma Sdn. Bhd., raising its shareholding to 82%; secured exclusive commercialization and distribution rights with Cosmo Pharmaceuticals to launch Winlevi cream in Singapore and Malaysia; obtained ASEAN commercialization rights from MC2 Therapeutics for Wynzora Cream; entered into an exclusive licensing agreement with Maruho Co., Ltd. for the anti-herpes virus agent amenamevir across ten ASEAN nations; extended its distribution partnership with medac GmbH for Metoject into Thailand and Cambodia; out-licensed its proprietary Cerapro MED formulation to Louis Widmer SA for European market distribution; expanded its Ceradan brand into the Gulf Cooperation Council markets; and initiated strategic preparations for a potential listing transfer to the Mainboard of the Singapore Exchange.